P102 Outcomes of biosimilar adalimumab switchbacks/reverse switching in IBD: real-world experience

Abstract

and time to discontinuation is shown in table 1. There were no associated factors with time to discontinuation. Maintenance frequency of 12 weeks was half as likely to be associated with discontinuation, but not statistically significant. Only 8/44 on 8-weekly maintenance frequency de-escalated to 12weekly. Conclusion Only a third of CD patients discontinued ustekinumab at 2 years follow-up and 5% discontinued therapy between year 1 and 2 of treatment. This suggests clinical response within the first year of treatment is likely to be sustained for another year. None of the patient, disease or drugrelated factors predicted drug discontinuation.